Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
Lei Huang,1 Kun Xie,1 Hongwen Li,1 Ruiqin Wang,1 Xiaoqing Xu,1 Kaiming Chen,1 Hua Gu,1 Jianmin Fang1– 3 1Laboratory of Molecular Medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, People&rsquo...
Main Authors: | Huang L, Xie K, Li H, Wang R, Xu X, Chen K, Gu H, Fang J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-08-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/suppression-of-c-met-overexpressing-tumors-by-a-novel-c-metcd3-bispeci-peer-reviewed-article-DDDT |
Similar Items
-
Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy
by: Hong Zhang, et al.
Published: (2024-01-01) -
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
by: Qingyun Yuan, et al.
Published: (2021-01-01) -
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01) -
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
by: Linyan Cheng, et al.
Published: (2024-04-01) -
Bispecific antibodies: a novel approach for targeting prominent biomarkers
by: Akshita Gupta, et al.
Published: (2020-11-01)